Targeting cofilin regulation through LIMK1 inhibitors or SSH activators presents a promising therapeutic strategy for AD; however, significant challenges remain in translating these findings into clinical approaches, particularly because other scientific evidence suggests the opposite, that is the excessive inactivation of the LIMK1-cofilin-actin axis may be responsible for the adverse effects observed in AD neurons. Here, LIMK1 is linked to Alzheimer disease.